Colitis and Cancer: What’s the Connection?

Chronic colitis, particularly the forms caused by ulcerative colitis and Crohn’s disease, raises the risk of developing colorectal cancer. A meta-analysis of population-based studies found that people with ulcerative colitis face roughly 2.4 times the colorectal cancer risk of the general population.¹ That risk is not automatic, though. It depends on how long the inflammation has been present, how much of the colon is involved, and whether certain compounding conditions exist. Modern surveillance and medication have brought rates down over time, but the gap between people with inflammatory bowel disease and those without it has not fully closed.²

How Much Higher Is the Risk, and for Whom?

Both ulcerative colitis and Crohn’s disease carry an elevated cancer risk, though the connection was recognized earlier and studied more thoroughly in ulcerative colitis. Crohn’s disease increases the risk of cancer at both colon and small-bowel sites, with the colon risk most relevant when Crohn’s inflammation involves a large portion of the large intestine.³ The more of the colon that is inflamed, the greater the danger. People with pancolitis, meaning inflammation throughout the entire colon, face substantially higher odds than those whose disease is limited to the left side or the rectum alone.

Duration is the other major driver. One study of 100 ulcerative colitis patients who went on to develop colorectal cancer found that the average time from colitis diagnosis to cancer diagnosis was about 21 years, regardless of whether the disease was extensive or left-sided.⁴ That figure helps explain why surveillance guidelines typically ramp up once a person has had the disease for eight to ten years.

Severity of inflammation matters independently of extent and duration. A study that matched ulcerative colitis patients found that repeated episodes of higher endoscopic inflammation scores were linked to a roughly 60 percent increase in the hazard of developing dysplasia or cancer.⁵ In other words, having flares that keep coming back is itself a risk factor, separate from simply having a long disease history. Family history of colorectal cancer also adds to the risk, and the combination of multiple risk factors can push individual odds considerably above the population average.⁶

People Diagnosed Young Face a Longer Exposure Window

Children and teenagers diagnosed with inflammatory bowel disease accumulate years of chronic inflammation earlier in life, which means the cancer risk clock starts ticking sooner. A large Swedish cohort study following childhood-onset IBD patients found that those with longstanding colitis of ten or more years had about four times the cancer risk of the general population.⁷ Other data paint an even starker picture for the longest follow-ups: the absolute risk of colorectal cancer 35 years after a pancolitis diagnosis was estimated at 30 percent, climbing to 40 percent in those diagnosed before age 15.⁸ Those numbers underscore why lifelong surveillance is especially critical for people whose disease started in childhood.

Why Chronic Inflammation Leads to Cancer

The cancer that arises from colitis follows a different biological path from the more common “sporadic” colorectal cancers that develop from polyps in people without inflammatory bowel disease. In sporadic cases, the sequence usually runs from a benign polyp to increasingly abnormal tissue to full cancer. In colitis-associated cancer, the precursor is dysplasia, patches of abnormal-looking cells arising in flat or subtly changed mucosa rather than an obvious polyp.⁹ The order of genetic mutations is also reshuffled: changes to the p53 tumor-suppressor gene tend to happen early in colitis-associated cancer, while in sporadic cases p53 mutations come later in the process.

At the tissue level, chronic inflammation generates reactive oxygen species that physically damage DNA. Research in both human tissue and mouse models has shown a strong correlation between the degree of intestinal inflammation and the amount of oxidative DNA damage in the colon lining.¹⁰ The more inflamed the tissue, the more damaged the DNA, and that damage accumulates over decades of disease.

Inflammatory signaling molecules also play a direct role. IL-6, a cytokine that surges during active colitis, activates a pathway that drives cell growth and blocks the normal self-destruct mechanism that damaged cells are supposed to undergo.¹¹ Think of it as inflammation telling damaged cells to keep dividing instead of dying off. Over time, those cells accumulate more mutations, and the system edges closer to cancer. This pathway is so well characterized that it has become a target for drug development.¹²

The Gut Barrier and the Microbiome

The colon is lined by a single layer of cells held together by proteins called tight junctions, forming a barrier between the gut’s interior and the body’s deeper tissues. In inflammatory bowel disease, this barrier breaks down. When it does, toxins and bacteria from inside the gut gain access to the tissue underneath, amplifying inflammation and increasing oxidative stress in a vicious cycle.¹³ Research has shown that disruptions to specific tight-junction proteins in the colon lining are a hallmark of both IBD and the transition to colitis-associated cancer.¹⁴ In mouse models, knocking out a key protein involved in maintaining this barrier leads to increased permeability, bacterial invasion, and accelerated cancer development.¹⁵

The bacteria themselves also change. People with colitis-associated cancer harbor a different microbial community on their gut lining compared to those with colitis alone. Certain bacterial families become overrepresented while others drop off.¹⁶ One consequence of these shifts is a reduction in butyrate, a short-chain fatty acid produced when gut bacteria ferment dietary fiber. Butyrate serves as the primary fuel for colon cells and has anti-cancer properties: it helps maintain the gut lining’s integrity and can suppress tumor-cell growth.¹⁷ When the microbial ecosystem tips in the wrong direction, butyrate production falls, and one of the colon’s built-in defenses weakens.

Epigenetic Changes Add Another Layer

Beyond straightforward DNA mutations, colitis-associated cancer involves epigenetic changes, alterations that affect how genes are read without changing the DNA sequence itself. Chronic inflammation can cause promoter regions of tumor-suppressor genes to become chemically silenced, effectively switching off the genes that are supposed to put the brakes on cell growth. At the same time, inflammation reshapes the proteins around which DNA is wound, changing which genes are accessible for transcription. Small regulatory molecules called microRNAs also become dysregulated, influencing multiple pathways involved in both inflammation and tumor growth.¹⁸ Mouse models lacking the protective mucus layer in the colon have shown that aberrant microRNA expression in the colon lining is directly involved in the transformation from chronic colitis to cancer.¹⁹

Primary Sclerosing Cholangitis as a Compounding Risk

Primary sclerosing cholangitis, a chronic liver condition that affects the bile ducts, overlaps with ulcerative colitis in a troubling way. Many people with PSC also have UC, and the combination magnifies cancer risk far beyond what either condition produces alone. A large Scandinavian study found that PSC patients had about 7.5 times the colorectal cancer risk of matched controls, with cumulative incidence climbing to 11 percent within 30 years of diagnosis.²⁰ An earlier study reported that a quarter of UC patients who also had PSC eventually developed colorectal cancer or dysplasia, compared to about 6 percent of UC patients without PSC.²¹ Because of this, guidelines recommend especially intensive colonoscopic surveillance for anyone who has both conditions.²²

Surveillance That Actually Catches Precancerous Changes

Because colitis-associated cancer often begins as flat dysplasia rather than a raised polyp, standard colonoscopy with random biopsies can miss it. Techniques that improve the view have become central to surveillance. Chromoendoscopy, in which a dye is sprayed onto the colon lining during a scope to highlight subtle surface patterns, roughly doubles the chance of detecting dysplasia compared to older standard-definition white-light endoscopy.²³ A meta-analysis found that for every 14 patients examined with chromoendoscopy instead of white-light endoscopy, one additional case of dysplasia was detected.²⁴

Newer high-definition white-light systems have narrowed the gap. A randomized trial comparing high-definition white-light endoscopy with random biopsies, high-definition white-light with targeted biopsies, and chromoendoscopy with targeted biopsies found that both the random-biopsy group and the chromoendoscopy group outperformed targeted biopsies taken under plain high-definition light.²⁵ The takeaway for patients is that the quality of the scope matters and that you should ask your gastroenterologist which technique they use during surveillance.

An emerging alternative to colonoscopy-based surveillance is stool-based DNA testing. A multi-site study tested a stool DNA panel in IBD patients and found it detected about 73 percent of colorectal cancers and 76 percent of all advanced colorectal neoplasia, with specificity around 81 percent in people without neoplasia.²⁶ Stool tests are not yet a replacement for colonoscopy in IBD surveillance, but they could become a useful tool for stratifying risk or filling in the gaps between scoping appointments.

Medications That May Lower the Risk

If chronic inflammation is the engine driving cancer risk, it stands to reason that controlling inflammation should slow that engine down. The evidence supports this, though the picture varies by drug class and disease type.

5-aminosalicylic acid (5-ASA), the backbone anti-inflammatory treatment for mild-to-moderate ulcerative colitis, is associated with a meaningful reduction in cancer risk. A meta-analysis found that 5-ASA use cut the odds of colorectal cancer in UC patients by about 60 percent.²⁷ A more recent meta-analysis confirmed the protective association with non-sulfasalazine 5-ASAs and estimated roughly a 22 percent reduction in colorectal cancer or dysplasia risk across IBD patients.²⁸ The difference in the magnitude of protection reported across studies likely reflects different comparison groups and study designs, but the direction is consistent: staying on 5-ASA therapy helps.

Biologic therapies, particularly anti-TNF drugs, have also shown a protective effect. The same recent meta-analysis found that anti-TNF biologics reduced colorectal cancer risk by about 22 percent in UC patients, though the effect was not significant in Crohn’s disease.²⁸ Another study found that biologic use was associated with a substantially reduced risk of advanced-stage intestinal cancer in UC.²⁹ Immunomodulators like azathioprine and methotrexate, by contrast, have not shown a clear independent cancer-protective effect in meta-analyses.²⁸

None of this means medication eliminates the risk. It means that effective inflammation control, particularly with 5-ASAs and anti-TNF biologics, appears to lower it. Staying on prescribed maintenance therapy even during remission is one of the most practical things a patient can do.

What Happens After Surgery

For people who develop high-grade dysplasia or cancer, or whose disease is medically uncontrollable, surgical removal of the colon (proctocolectomy) followed by construction of an internal pouch from the small intestine is often the recommended approach.³⁰ This procedure dramatically reduces colorectal cancer risk, but it does not eliminate it entirely. A small amount of rectal or transitional-zone tissue is usually left behind at the junction where the pouch meets the anal canal, and cancer can occasionally develop there.

A systematic review found that the cumulative incidence of pouch-related adenocarcinoma after surgery for UC was about 0.3 percent at 20 years, with most cancers arising from the remaining anorectal cuff rather than the pouch itself.³¹ A separate meta-analysis of nearly 20,000 UC patients who had undergone pouch surgery reported a pooled pouch-cancer incidence of about 0.3 percent, with the majority of these cancers found in the pouch body.³² Those numbers are reassuringly low, but they mean that even after surgery, periodic endoscopic monitoring of the pouch is warranted.

Immune Checkpoint Inhibitor Colitis Is a Different Story

Not all colitis carries the same cancer implications. Colitis triggered by immune checkpoint inhibitors, the drugs used in cancer immunotherapy, looks similar to IBD under a microscope and on endoscopy but behaves differently. This form of colitis is typically acute rather than chronic, features more short-term inflammatory cells rather than the chronic architectural changes of longstanding IBD, and responds to corticosteroids or, when those fail, to infliximab or vedolizumab.³³ Because it does not involve the same decades-long cycle of inflammation, barrier breakdown, and accumulated DNA damage, checkpoint-inhibitor colitis is not currently considered a risk factor for future colorectal cancer in the same way as IBD-related colitis. If you develop colitis while on immunotherapy for another cancer, the concern is managing the colitis itself and deciding whether to continue the immunotherapy, not long-term colorectal cancer surveillance.

The Immune Cells That Build a Tumor-Friendly Neighborhood

One of the less intuitive aspects of the colitis-cancer link is that inflammation does not just damage DNA. It also reshapes the cellular neighborhood around developing tumors in ways that help them survive. In mouse models of colitis-associated cancer, immune-suppressive cells called myeloid-derived suppressor cells accumulate at higher levels in tumors than in surrounding inflamed tissue.³⁴ These cells dampen the immune system’s ability to recognize and attack early-stage cancers. Research has shown that inflammatory signaling molecules produced by macrophages in the gut promote the accumulation of these suppressor cells, creating a feedback loop: inflammation breeds immune suppression, which shields abnormal cells from immune surveillance, which lets tumors grow.³⁵ Understanding this process is one reason researchers are interested in whether targeted immune therapies might one day prevent colitis-associated cancer, not just treat the inflammation that precedes it.